PMID- 34582101
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2045-7022 (Print)
IS  - 2045-7022 (Electronic)
IS  - 2045-7022 (Linking)
VI  - 11
IP  - 7
DP  - 2021 Sep
TI  - Relationship between longitudinal changes in type-2 inflammation, immunoglobulin 
      E sensitization, and clinical outcomes in young asthmatics.
PG  - e12066
LID - 10.1002/clt2.12066 [doi]
LID - e12066
AB  - BACKGROUND: Asthma is a heterogeneous condition where biomarkers may be of 
      considerable advantage in diagnosis and therapy monitoring. However, the changes 
      in asthma biomarkers and immunoglobulin E (IgE) over the course of life has not 
      been extensively investigated. OBJECTIVE: To study longitudinal changes in type-2 
      inflammatory biomarkers, IgE, and clinical outcomes, and the association between 
      these changes, in young asthmatics. METHODS: Asthmatics (age 10-35 years, 
      n = 253) were examined at baseline and at a follow-up visit, 43 [23-65] (median 
      [range]) months later. Subjects were analyzed using the multi-allergen tests 
      Phadiatop and fx5 (ImmunoCAP) and grouped based on the baseline allergen-specific 
      IgE antibody (sIgE) concentration: <0.10, 0.10-0.34, and >/=0.35 kU(A) /L. The 
      relationship between changes (Delta values) in type-2 biomarkers (individualized 
      fraction of exhaled nitric oxide [FeNO%], blood eosinophil [B-Eos] count, total 
      IgE [tIgE] and sIgE, lung function [% predicted forced expiratory volume in 1 
      second (FEV(1) ) and FEV(1) /forced vital capacity (FVC)], and Asthma Control 
      Test [ACT]) score were determined. RESULTS: At follow up, FEV(1) and FEV(1) /FVC 
      had decreased (93.6% vs. 95.8%, and 93.4% vs. 94.7% of predicted, respectively 
      [p < 0.001 both]), whereas ACT score had increased (21.6 vs. 20.6, p = 0.001). A 
      significant decline in lung function was seen in subjects with sIgE >/= 0.10 kUA/L, 
      but not in those with undetectable sIgE (<0.10 kU(A) /L). Furthermore, tIgE and 
      sIgE declined over time (p < 0.001 all) whereas FeNO% and B-Eos count were not 
      significantly changed. In univariate analysis, significant negative correlations 
      between ∆B-Eos count and ∆FeNO%, on one hand, and changes in lung function, on 
      the other hand, were seen, and multivariate analysis showed an independent 
      relationship between DeltaFeNO%, and DeltaFEV(1) (p < 0.05) and DeltaFEV(1) /FVC% (p < 0.01). 
      Sex-specific analysis showed that the independent association between DeltaFeNO%, and 
      DeltaFEV(1) remained only in females (p = 0.005), and there was a significant 
      interaction with sex (p = 0.02). CONCLUSION: In young asthmatics, IgE levels 
      declined over 43 months, whereas FeNO and B-Eos remained unchanged. In spite of 
      improved asthma control, an accelerated lung function decline was seen in 
      patients with detectable sIgE at baseline, and the decline correlated with 
      changes in type-2 biomarkers. Particularly, the increase in individualized FeNO 
      associated independently with decline in FEV(1) in females.
CI  - (c) 2021 The Authors. Clinical and Translational Allergy published by John Wiley & 
      Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
FAU - Tsolakis, Nikolaos
AU  - Tsolakis N
AUID- ORCID: 0000-0002-2918-7273
AD  - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
FAU - Jacinto, Tiago
AU  - Jacinto T
AD  - University of Porto, Porto, Portugal.
FAU - Janson, Christer
AU  - Janson C
AD  - Medical Sciences, Uppsala University, Uppsala, Sweden.
FAU - Borres, Magnus
AU  - Borres M
AD  - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
AD  - ImmunoDiagnostics, Thermo Fisher Scientific, Uppsala, Sweden.
FAU - Malinovschi, Andrei
AU  - Malinovschi A
AUID- ORCID: 0000-0002-4098-7765
AD  - Medical Sciences, Uppsala University, Uppsala, Sweden.
FAU - Alving, Kjell
AU  - Alving K
AD  - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
LA  - eng
GR  - Thermo Fisher Scientific/
GR  - Hjart-Lungfonden/
GR  - Gillberg's Foundation/
GR  - Bror Hjerpstedt's Foundation/
GR  - Hesselman's Foundation/
GR  - Swedish Foundation for Strategic Research/
GR  - Swedish Heart and Lung Foundation/
GR  - Swedish Asthma and Allergy Association's Research Foundation/
PT  - Journal Article
PL  - England
TA  - Clin Transl Allergy
JT  - Clinical and translational allergy
JID - 101576043
PMC - PMC9083004
OTO - NOTNLM
OT  - IgE
OT  - NO
OT  - asthma
OT  - eosinophils
COIS- Magnus Borres is an employee of Thermo Fisher Scientific, and Kjell Alving has 
      received research material from the same company and from Hemocue. None of the 
      other authors declare conflict of interest.
EDAT- 2021/09/29 06:00
MHDA- 2021/09/29 06:01
PMCR- 2021/09/27
CRDT- 2021/09/28 12:33
PHST- 2021/08/25 00:00 [revised]
PHST- 2021/04/22 00:00 [received]
PHST- 2021/09/16 00:00 [accepted]
PHST- 2021/09/28 12:33 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2021/09/29 06:01 [medline]
PHST- 2021/09/27 00:00 [pmc-release]
AID - CLT212066 [pii]
AID - 10.1002/clt2.12066 [doi]
PST - ppublish
SO  - Clin Transl Allergy. 2021 Sep;11(7):e12066. doi: 10.1002/clt2.12066.